{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T13:23:29Z","timestamp":1778073809099,"version":"3.51.4"},"reference-count":11,"publisher":"Universa BV","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Olmesartan is an angiotensin II receptor blocker (ARB) used for the management of hypertension. We report a case of Olmesartan-associated severe gastritis and enteropathy (OAE) in a 81-year-old female patient who presented with anorexia and weight loss. After discontinuation of the drug, her symptoms improved and follow-up gastroscopy showed endoscopic improvement. Histopathology showed a reduction of eosinophils and intraepithelial lymphocytosis, but a persisting increase in mast cells. Hence, systemic mastocytosis was excluded by further investigations. To our knowledge, this is the first case report of a patient with Olmesartan-associated severe gastritis with histopathological presence of mast cells. We conclude that mast cells, like eosinophils, could be druginduced, although systemic mastocytosis must be ruled out. Future studies should focus on the link between local mast cells and gastro-intestinal diseases.<\/jats:p>","DOI":"10.51821\/88.1.13942","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:52:27Z","timestamp":1751280747000},"page":"203","source":"Crossref","is-referenced-by-count":2,"title":["Atypical presentation of Olmesartan-induced gastritis and enteropathy"],"prefix":"10.51821","volume":"88","author":[{"given":"H","family":"Schreurs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Breynaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"De Hertogh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Wauters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"MICHEL MC., FOSTER C., BRUNNER HR., LIU L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013 Apr;65(2):809\u201348.","DOI":"10.1124\/pr.112.007278"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"CHOI E-YK., MCKENNA BJ. Olmesartan-Associated Enteropathy: AReview of Clinical and Histologic Findings. Arch Pathol Lab Med. 2015 Oct;139(10):1242\u20137.","DOI":"10.5858\/arpa.2015-0204-RA"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"THEOPHILE H., DAVID X-R., MIREMONT-SALAME G., HARAMBURU F. Five cases of sprue-like enteropathy in patients treated by olmesartan. Dig liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2014 May;46(5):465\u20139.","DOI":"10.1016\/j.dld.2013.12.014"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"GENTILE NM., MURRAY JA., PARDI DS. Autoimmune enteropathy: a review and update of clinical management. Curr Gastroenterol Rep. 2012 Oct;14(5):380\u20135.","DOI":"10.1007\/s11894-012-0276-2"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"EBRAHIM VS., MARIN J., MURTHY S., ODSTRCIL E., HUANG H., POLTER D. Olmesartan-associated enteropathy. Vol. 30, Proceedings (Baylor University. Medical Center). United States; 2017. p. 348\u201350.","DOI":"10.1080\/08998280.2017.11929644"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"RUBIO-TAPIA A., HERMAN ML, LUDVIGSSON JF., KELLY DG., MANGAN TF., WU T-T, et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012 Aug;87(8):732\u20138.","DOI":"10.1016\/j.mayocp.2012.06.003"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"KIRSHENBAUM AS., GOFF JP., SEMERE T., FOSTER B., SCOTT LM., METCALFE DD. Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13). Blood. 1999 Oct;94(7):2333\u201342.","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"JAKATE S., DEMEO M., JOHNA R., TOBIN M., KESHAVARZIANA. Mastocytic enterocolitis: increased mucosal mast cells in chronic intractable diarrhea. Arch Pathol Lab Med. 2006 Mar;130(3):362\u20137.","DOI":"10.5858\/2006-130-362-MEIMMC"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"SHENBAGARAJ L, SWIFT G. Olmesartan-associated severe gastritis and enteropathy. BMJ Case Rep. 2018 Dec;11(1).","DOI":"10.1136\/bcr-2018-226133"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"HARTRANFT ME., REGAL RE. \u201cTriple Phase\u201d Budesonide Capsules forthe Treatment of Olmesartan-Induced Enteropathy. Ann Pharmacother. 2014 Sep;48(9):1234\u20137.","DOI":"10.1177\/1060028014540608"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"IANIRO G, BIBBO S, MONTALTO M, RICII R, GASBARRINI A, CAMMAROTA G. Systematic review: Sprue-like enteropathy associated with olmesartan. Aliment Pharmacol Ther. 2014 Jul;40(1):16\u201323.","DOI":"10.1111\/apt.12780"}],"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:52:31Z","timestamp":1751280751000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2242\/Atypical%20presentation%20of%20Olmesartan-induced%20gastritis%20and%20enteropathy\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":11,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.51821\/88.1.13942","relation":{},"ISSN":["1784-3227","1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"},{"value":"1784-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]}}}